Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Gross Margin (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Gross Margin for 13 consecutive years, with 8.06% as the latest value for Q3 2025.

  • On a quarterly basis, Gross Margin changed N/A to 8.06% in Q3 2025 year-over-year; TTM through Sep 2025 was 110.81%, a 4815.0% increase, with the full-year FY2024 number at 66.26%, up 807.0% from a year prior.
  • Gross Margin was 8.06% for Q3 2025 at NovaBay Pharmaceuticals, down from 65.05% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q1 2023 to a low of 8.06% in Q3 2025.
  • A 5-year average of 58.65% and a median of 55.86% in 2022 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: crashed -2102bps in 2022, then skyrocketed 4458bps in 2023.
  • NovaBay Pharmaceuticals' Gross Margin stood at 37.93% in 2021, then grew by 27bps to 48.17% in 2022, then grew by 7bps to 51.55% in 2023, then grew by 26bps to 65.05% in 2024, then plummeted by -88bps to 8.06% in 2025.
  • Per Business Quant, the three most recent readings for NBY's Gross Margin are 8.06% (Q3 2025), 65.05% (Q4 2024), and 49.27% (Q2 2024).